Johnson & Johnson (JNJ)

Healthcare · Drug Manufacturers - General · S&P 500
$254.78 +0.73% on the day Market cap $616.8B 52-week range $182.94 to $281.07 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
11% a year for 10 years

At a market value of $616.8B, Johnson & Johnson's free cash flow of $19.7B (fiscal 2025) would need to grow about 11% a year for the stock to be worth today's price. That is faster than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Johnson & Johnson's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price10.9% a year
Free cash flow, last 9 years2.7% a year
Revenue, same period3.0% a year
Price to free cash flow31.3x

Fundamental grade

C

Five factors scored 1 to 9 from JNJ's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation4
Profitability8
Growth2
Financial health3
Cash efficiency9

Key numbers

P/E (trailing)29.7x
P/E (forward)21.9x
Price / free cash flow31.3x
EV / EBITDA19.0x
Price / sales6.30x
Price / book7.52x
Revenue growth+6.6%
Operating margin—
Net margin21.5%
Return on equity24.8%
Dividend yield2.1%
Debt / equity1.37x

Results from SEC filings

Fiscal years, from Johnson & Johnson's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$78.7B$80.0B$85.2B$88.8B$94.2B
Net income$20.9B$17.9B$35.2B$14.1B$26.8B
Free cash flow$19.8B$17.2B$18.2B$19.8B$19.7B
EPS (diluted)$7.81$6.73$13.72$5.79$11.03
Operating margin—————

Where the revenue comes from

Revenue by segments, fiscal 2025.

Innovative Medicine$60.4B64%
MedTech$33.8B36%

Superinvestors who own JNJ

From each investor's latest 13F filing (what a 13F shows). 17 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Hersh Cohen
ClearBridge Investments
Trimmed $1.4B1.1%Q2 2026
Cliff Asness
AQR Capital Management
Trimmed $738M0.26%Q2 2026
Donald Yacktman
Yacktman Asset Management
Added $320M4.0%Q2 2026
Tom Gayner
Markel Group Inc.
Held $155M1.2%Q2 2026
Tom Steyer
Farallon Capital Management LLC
Added $104M0.48%Q2 2026
Charles Brandes
Brandes Investment Partners, LP
Trimmed $70M0.49%Q2 2026
Tweedy, Browne
Tweedy, Browne Company
Trimmed $51M3.9%Q2 2026
Joel Greenblatt
Gotham Asset Management
Trimmed $51M0.12%Q2 2026
Mario Gabelli
GAMCO Investors
Trimmed $20M0.18%Q2 2026
Prem Watsa
Fairfax Financial Holdings
Held $19M0.71%Q2 2026
John Rogers
Ariel Investments
Trimmed $9M0.09%Q2 2026
Ron Baron
Baron Capital (BAMCO)
Added $6M0.01%Q2 2026

Insider buying

Open-market purchases by Johnson & Johnson's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Mar 10, 2026 Lloyd Doggett
0$243.75—
Mar 10, 2026 Lloyd Doggett
0$243.75—
Mar 10, 2026 Lloyd Doggett
0$243.75—
Feb 5, 2026 Ro Khanna
0$237.66—
Feb 5, 2026 Ro Khanna
0$237.66—
Feb 5, 2026 Ro Khanna
0$237.66—
Dec 9, 2025 Lloyd Doggett
0$199.99—
Dec 9, 2025 Lloyd Doggett
0$199.99—
Dec 9, 2025 Lloyd Doggett
0$199.99—
Nov 7, 2025 Ro Khanna
0$186.50—

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when JNJ trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Johnson & Johnson's stock price imply?

At a market value of $616.8B, Johnson & Johnson would need its free cash flow to grow about 11% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 3% a year.

Are Johnson & Johnson insiders buying the stock?

10 open-market insider purchases of JNJ in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Johnson & Johnson?

17 of the superinvestors Investingly tracks hold JNJ in their latest 13F, including Hersh Cohen, Cliff Asness, Donald Yacktman.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.